Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EBITDA: 2013-2024

Historic EBITDA for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to -$87.0 million.

  • Zevra Therapeutics' EBITDA rose 115.17% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.7 million, marking a year-over-year decrease of 1.07%. This contributed to the annual value of -$87.0 million for FY2024, which is 75.40% down from last year.
  • Zevra Therapeutics' EBITDA amounted to -$87.0 million in FY2024, which was down 75.40% from -$49.6 million recorded in FY2023.
  • Over the past 5 years, Zevra Therapeutics' EBITDA peaked at $7.7 million during FY2021, and registered a low of -$87.0 million during FY2024.
  • Moreover, its 3-year median value for EBITDA was -$49.6 million (2023), whereas its average is -$59.7 million.
  • As far as peak fluctuations go, Zevra Therapeutics' EBITDA soared by 237.80% in 2021, and later crashed by 650.72% in 2022.
  • Over the past 5 years, Zevra Therapeutics' EBITDA (Yearly) stood at -$5.6 million in 2020, then soared by 237.80% to $7.7 million in 2021, then slumped by 650.72% to -$42.6 million in 2022, then declined by 16.54% to -$49.6 million in 2023, then tumbled by 75.40% to -$87.0 million in 2024.